CHICAGO--(BUSINESS WIRE)--Tempus, a leader in AI-enabled diagnostics, today unveiled a breakthrough technology for oncologists, Tempus ONE. This smart, voice-enabled, portable device brings Tempus’ proprietary platform and unparalleled library of multi-modal data to life, offering physicians real-time access to all the clinical insights and data contained in Tempus’ genomic reports in the palm of their hand. In beta today and launching more broadly in 2021, Tempus ONE is the first step toward bringing the full power of artificial intelligence to the point-of-care.
Tempus’ multi-omic molecular tests arm oncologists with their patients’ actionable genetic alterations, and the company’s proprietary platform connects that data to phenotypic and morphologic patient data, including longitudinally-updated outcome data from electronic health records (EHR), to provide clinical context to every test. To alleviate the amount of time clinicians must spend on their computers, Tempus has designed ONE as a portable device with the ability to relay all of the information contained in its reports, along with vast amounts of relevant additional data regarding that patient, in real-time, seamlessly integrating into their existing workflow. The handheld, cube-like device takes questions and input from physicians through an embedded microphone array and produces a response for playback through its proprietary voice-activated speaker system specifically designed with physicians’ needs in mind.
“For the past 5 years we have been on a journey to bring the promise and power of artificial intelligence to healthcare,” said Eric Lefkofsky, Founder and CEO of Tempus. “Tempus ONE is a quantum leap forward, harnessing the almost 30 petabytes of data we have collected in the past few years, which we embedded into a device that fits in the palm of your hand and puts the full breadth and scope of our technology platform in the hands of every doctor we serve, enhancing their ability to use data in making real-time treatment decisions.”
“Tempus created a learning healthcare system at massive scale that gains intelligence and insights with each stream of data and interaction,” says Joel Dudley, Chief Scientific Officer of Tempus. “Tempus ONE enables clinicians to interact with vast Tempus information resources as they would interact with other members of their care team. At the same time, every question and conversation posed to Tempus ONE improves our ability to deliver the highest-quality information and insights to the next patient case.”
Tempus ONE is in beta release and will only be made available to selected oncologists during the pre-launch phase. For more information, please visit tempus.com/tempus-one.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.